Expression of CD14, IL10, and Tolerogenic Signature in Dendritic Cells Inversely Correlate with Clinical and Immunologic Response to TARP Vaccination in Prostate Cancer Patients
/in Dendritic Cells, International Publications, Prostate Cancer /von 2017-01-10 / Clin. Cancer Res. 2017 07;23(13):3352-3364Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy
/in Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-06 / Pharmacotherapy 2017 01;37(1):129-143Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Multiple Myeloma /von 2017-01-01 / Curr Cancer Drug Targets 2017;17(9):782-805Progress in Vaccine Therapies for Breast Cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2017-01-01 / Adv Exp Med Biol 2017;1026:315-330Dendritic cell-based immunotherapy
/in Dendritic Cells, International Publications /von 2016-12-27 / Cell Res. 2017 Jan;27(1):74-95The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
/in Dendritic Cells, International Publications, Prostate Cancer /von 2016-12-20 / J Immunother Cancer 2016;4:92Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial
/in Breast Cancer, Dendritic Cells, International Publications /von 2016-12-13 / Clin Cancer Res 2017 Jun;23(12):2961-2971Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions
/in Acute Leukemia, Dendritic Cells, International Publications /von 2016-12-07 / Sci Transl Med 2016 12;8(368):368ra171Emerging role of immunotherapy in urothelial carcinoma-Advanced disease
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma /von 2016-12-01 / Urol Oncol 2016 12;34(12):538-547IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de